Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Julie Nangia"'
Autor:
Valentina Hoyos, Spyridoula Vasileiou, Manik Kuvalekar, Ayumi Watanabe, Ifigeneia Tzannou, Yovana Velazquez, Matthew French-Kim, Wingchi Leung, Suhasini Lulla, Catherine Robertson, Claudette Foreman, Tao Wang, Shaun Bulsara, Natalia Lapteva, Bambi Grilley, Matthew Ellis, Charles Kent Osborne, Angela Coscio, Julie Nangia, Helen E. Heslop, Cliona M. Rooney, Juan F. Vera, Premal Lulla, Mothaffar Rimawi, Ann M. Leen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Purpose: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigate
Externí odkaz:
https://doaj.org/article/d2a1cea135ca47b2969fd4c6813e68ff
Autor:
Nicole Higashiyama, Julie Nangia, Maryam Nemati Shafaee, Nan Chen, Binu Liz Michael, Mothaffar Rimawi, Valentina Hoyos
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 2, Iss , Pp 100034- (2020)
Trastuzumab deruxtecan has been shown to have responses in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, the safety of this medication in patients with severe liver dysfun
Externí odkaz:
https://doaj.org/article/b5ad9442d21e4a74a93f4dc5a74c051d
Autor:
Maryam Nemati Shafaee, Emily L Podany, Katherine Sanchez, Nicole Higashiyama, Valentina Hoyos, Liz Binu Micheal, Kristen Otte, Anne Pavlick, Julie Nangia, Alphi Kuriakose, Kent C Osborne, Maria Jibaja-Weiss, Matthew J Ellis, Shaun Bulsara, Mothaffar Rimawi
Publikováno v:
Cancer Research. 82:P5-14
Background: Patients with higher socioeconomic status (SES) are overrepresented in NCI-sponsored cancer clinical trials (CCT). Inadequate access, social and cultural barriers have been described as reasons for poor accrual of patients with low SES in
Autor:
Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King, Tyler Risom, Lunden Simpson, Sujay Vennam, Aziz Khan, Timothy Hardman, Bryan E Harmon, Fergus J Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla F McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair Thompson, Gaorav Gupta, Robyn Burns, Deborah J Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R Marks, Graham A Colditz, E Shelley Hwang, Robert B West
Publikováno v:
Cancer Research. 82:GS4-07
Background. DCIS consists of a molecularly heterogeneous group of premalignant lesions, with variable risk of invasive progression. Understanding biomarkers for invasive progression could help individualize treatment recommendations based upon tumor
Publikováno v:
Cancer Research. 82:P2-12
Background: Locally advanced triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer comprising 10-20% of new diagnoses each year. Optimization of neoadjuvant therapy is necessary to decrease risk of relapse. Carboplatin has be
Autor:
Neil Chevli, Kaidi Wang, Waqar Haque, Mary R. Schwartz, Julie Nangia, Jennifer Sasaki, Andrew M. Farach, Sandra S. Hatch, E. Brian Butler, Bin S. Teh
Publikováno v:
Cancer Research. 82:P3-19
Purpose/Objectives Mucinous carcinoma (MC) of the breast is an uncommon variant of breast cancer which has a favorable prognosis. Current guidelines for ER/PR-positive, HER2-negative pure-MC state that endocrine therapy (ET) is only required for tumo
Autor:
Siri H. Strand, Belén Rivero-Gutiérrez, Kathleen E. Houlahan, Jose A. Seoane, Lorraine M. King, Tyler Risom, Lunden A. Simpson, Sujay Vennam, Aziz Khan, Luis Cisneros, Timothy Hardman, Bryan Harmon, Fergus Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla F. McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair M. Thompson, Gaorav P. Gupta, Robyn Burns, Deborah J. Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X. Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Lauren Anderson, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R. Marks, Graham A. Colditz, E. Shelley Hwang, Robert B. West
Publikováno v:
Scientia
Strand, S H, Rivero-Gutiérrez, B, Houlahan, K E, Seoane, J A, King, L M, Risom, T, Simpson, L A, Vennam, S, Khan, A, Cisneros, L, Hardman, T, Harmon, B, Couch, F, Gallagher, K, Kilgore, M, Wei, S, DeMichele, A, King, T, McAuliffe, P F, Nangia, J, Lee, J, Tseng, J, Storniolo, A M, Thompson, A M, Gupta, G P, Burns, R, Veis, D J, DeSchryver, K, Zhu, C, Matusiak, M, Wang, J, Zhu, S X, Tappenden, J, Ding, D Y, Zhang, D, Luo, J, Jiang, S, Varma, S, Anderson, L, Straub, C, Srivastava, S, Curtis, C, Tibshirani, R, Angelo, R M, Hall, A, Owzar, K, Polyak, K, Maley, C, Marks, J R, Colditz, G A, Hwang, E S & West, R B 2022, ' Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ : Analysis of TBCRC 038 and RAHBT cohorts ', Cancer Cell, vol. 40, no. 12, pp. 1521-1536.e7 . https://doi.org/10.1016/j.ccell.2022.10.021
Strand, S H, Rivero-Gutiérrez, B, Houlahan, K E, Seoane, J A, King, L M, Risom, T, Simpson, L A, Vennam, S, Khan, A, Cisneros, L, Hardman, T, Harmon, B, Couch, F, Gallagher, K, Kilgore, M, Wei, S, DeMichele, A, King, T, McAuliffe, P F, Nangia, J, Lee, J, Tseng, J, Storniolo, A M, Thompson, A M, Gupta, G P, Burns, R, Veis, D J, DeSchryver, K, Zhu, C, Matusiak, M, Wang, J, Zhu, S X, Tappenden, J, Ding, D Y, Zhang, D, Luo, J, Jiang, S, Varma, S, Anderson, L, Straub, C, Srivastava, S, Curtis, C, Tibshirani, R, Angelo, R M, Hall, A, Owzar, K, Polyak, K, Maley, C, Marks, J R, Colditz, G A, Hwang, E S & West, R B 2022, ' Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ : Analysis of TBCRC 038 and RAHBT cohorts ', Cancer Cell, vol. 40, no. 12, pp. 1521-1536.e7 . https://doi.org/10.1016/j.ccell.2022.10.021
Ductal carcinoma in situ; Tumor microenvironment; Whole genome sequencing Carcinoma ductal in situ; Microambiente tumoral; Secuenciación del genoma completo Carcinoma ductal in situ; Microambient tumoral; Seqüenciació del genoma complet Ductal car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab5ce28cf6c965de1e61deadc35a7264
https://hdl.handle.net/11351/8732
https://hdl.handle.net/11351/8732
Autor:
Neil Chevli, Kaidi Wang, Waqar Haque, Mary R. Schwartz, Julie Nangia, Jennifer Sasaki, Andrew M. Farach, Sandra S. Hatch, E. Brian Butler, Bin S. Teh
Publikováno v:
Clinical breast cancer. 22(7)
Pure Mucinous breast carcinoma (PMBC) is an invasive breast cancer with favorable prognosis. While pathology-specific guidelines exist for PMBC regarding adjuvant chemotherapy and endocrine therapy, no recommendations exist regarding locoregional tre
Autor:
Polly, Niravath, Susan G, Hilsenbeck, Tao, Wang, Sao, Jiralerspong, Julie, Nangia, Anne, Pavlick, Foluso, Ademuyiwa, Ashley, Frith, Cynthia, Ma, Haeseong, Park, Caron, Rigden, Rama, Suresh, Matthew, Ellis, C, Kent Osborne, Mothaffar F, Rimawi
Publikováno v:
Breast cancer research and treatment. 177(2)
Half of hormone receptor-positive (HR+) breast cancer patients will develop joint pain, termed aromatase inhibitor-induced arthralgia (AIA), while taking aromatase inhibitor therapy. Though there is no universally accepted effective treatment for AIA